Literature DB >> 23512786

Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study.

Ranjeeta Bahirwani1, Burc Barin, Kim Olthoff, Peter Stock, Barbara Murphy, K Rajender Reddy.   

Abstract

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are both associated with chronic kidney disease (CKD), a major complication after orthotopic liver transplantation (OLT). The aim of this study was to assess predictors of post-OLT CKD in HIV/HCV-coinfected recipients versus HIV-infected recipients without HCV (HIV/non-HCV recipients). Data from a National Institutes of Health study of 116 OLT recipients (35 HIV/non-HCV recipients and 81 HIV/HCV-coinfected recipients) from 2003 to 2010 (Solid Organ Transplantation in HIV: Multi-Site Study) were analyzed for the pretransplant CKD prevalence [estimated glomerular filtration rate (eGFR) < 60 mL/minute for ≥3 months] and the incidence of CKD up to 3 years posttransplant. Proportional hazards models were performed to assess predictors of posttransplant CKD. A contemporaneous cohort of HCV-monoinfected transplant recipients from the Scientific Registry of Transplant Recipients database was also analyzed. The median age at transplant was 48 years, the median serum creatinine level was 1.1 mg/dL, and the median eGFR was 77 mL/minute. Thirty-four patients were suspected to have pretransplant CKD; 20 of these patients (59%) had posttransplant CKD. Among the 82 patients without pretransplant CKD (26 HIV/non-HCV patients and 56 HIV/HCV-coinfected patients), the incidence of stage 3 CKD 3 years after OLT was 62% (55% of HIV/non-HCV patients and 65% of HIV/HCV-coinfected patients), and the incidence of stage 4/5 CKD was 8% (0% of HIV/non-HCV patients and 12% of HIV/HCV-coinfected patients). In a multivariate analysis, older age [[hazard ratio (HR) = 1.05 per year, P = 0.03] and the CD4 count (HR = 0.90 per 50 cells/μL, P = 0.01) were significant predictors of CKD. HCV coinfection was significantly associated with stage 4/5 CKD (HR = 10.8, P = 0.03) after adjustments for age. The cumulative incidence of stage 4/5 CKD was significantly higher for HIV/HCV-coinfected patients versus HIV/non-HCV transplant recipients and HCV-monoinfected transplant recipients (P = 0.001). In conclusion, CKD occurs frequently in HIV-infected transplant recipients. Predictors of posttransplant CKD include older age and a lower posttransplant CD4 count. HCV coinfection is associated with a higher incidence of stage 4/5 CKD.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23512786      PMCID: PMC3667971          DOI: 10.1002/lt.23648

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.

Authors:  J Macías; I Melguizo; F J Fernández-Rivera; A García-García; J A Mira; A J Ramos; J M Rivera; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-11-09       Impact factor: 3.267

3.  Transplantation for patients infected with human immunodeficiency virus: no longer experimental but not yet routine.

Authors:  Jay A Fishman
Journal:  J Infect Dis       Date:  2003-11-12       Impact factor: 5.226

4.  Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK).

Authors:  J D Eason; T A Gonwa; C L Davis; R S Sung; D Gerber; R D Bloom
Journal:  Am J Transplant       Date:  2008-09-19       Impact factor: 8.086

5.  Chronic kidney disease after orthotopic liver transplantation: impact of hepatitis C infection.

Authors:  Ranjeeta Bahirwani; Oren Shaked; Shanu Kurd; Roy Bloom; K Rajender Reddy
Journal:  Transplantation       Date:  2011-06-15       Impact factor: 4.939

6.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

7.  Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.

Authors:  Norah A Terrault; Michelle E Roland; Thomas Schiano; Lorna Dove; Michael T Wong; Fred Poordad; Margaret V Ragni; Burc Barin; David Simon; Kim M Olthoff; Lynt Johnson; Valentina Stosor; Dushyantha Jayaweera; John Fung; Kenneth E Sherman; Aruna Subramanian; J Michael Millis; Douglas Slakey; Carl L Berg; Laurie Carlson; Linda Ferrell; Donald M Stablein; Jonah Odim; Lawrence Fox; Peter G Stock
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

Review 8.  CKD in HIV-infected patients other than HIV-associated nephropathy.

Authors:  Ajay K Rachakonda; Paul L Kimmel
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

9.  The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.

Authors:  Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2008-02       Impact factor: 8.860

10.  Chronic renal failure after transplantation of a nonrenal organ.

Authors:  Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

View more
  1 in total

1.  Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease.

Authors:  Anna Maruyama; Trana Hussaini; Nilufar Partovi; Siegfried R Erb; Vladimir Marquez Azalgara; Nadia Zalunardo; Neora Pick; Mark Hull; Eric M Yoshida
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-03-30       Impact factor: 2.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.